Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for the patients suffering from serious diseases with high unmet medical need. The firm particularly develops a therapeutic drug to treat autoimmune diseases in particular lupus nephritis. Its main product candidate is Voclosporin.
| Website: | www.auriniapharma.com |
| Email: | dbourgeault@auriniapharma.com |
| Main Phone: | +1 250 744-2487 |
| Address: | 4464 Markham Street |
| Address 2: | Suite 1203 |
| State: | BC |
| City / Town: | Victoria |
| Country: | CAN |
| Postal Code: | V8Z 7X8 |
| Exchange: | TSX |
| CEO: | Richard M. Glickman |
| Employees: | 33 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange TSX |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 20.94 | 20.94 | 20.94 | 20.94 |
| Low Target Price Estimate | 12.8 | 12.8 | 12.8 | 12.8 |
| Mean Target Price Estimate | 16.27 | 16.27 | 16.27 | 16.27 |
| Standard Deviation | 3.2 | 3.2 | 3.2 | 3.2 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 06/25/18 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 |
| Moderate Buy | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.41 | 1.41 | 1.41 | 1.41 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
